The relation between HIV- 1 integration and latency
|
|
- Anne Marshall
- 5 years ago
- Views:
Transcription
1 The relation between HIV- 1 integration and latency Linos Vandekerckhove HIV translational research, Ghent Department of General Internal Medicine, Infectious Diseases and Psychosomatic Medicine University Hospital Ghent
2 Agenda Mechanism Of HIV integration Of HIV latency Quantification of HIV Integration Quantification of HIV Reservoir The relation between residual viremia and integration events The relation between integration and latency Can we interfere with integration to diminish latency and residual viremia?
3 HIV-1 virion grupo3/hiv.jpg
4 Genomic organization and structure of the HIV-1 virion 5 CAP R U5 gag pol vpr vif vpu tat rev env nef U3 R AAA 3 gp41(tm) gp120(su) p32(in) p66/p51(rt) p10(pr) p17(ma) p7(nc) p24(ca) Lipid bilayer (can contain cellular proteins, e.g. HLA) Genomic RNA
5 HIV-1 replication cycle and HAART (Highly Active Antiretroviral Therapy) gp 120 CD4 Entry Inhibitors CXCR4 CCR5 Protease inhibitors LTR HIV-1 LTR Reverse transcriptase inhibitors Integrase inhibitors
6 HIV integration occurs in several steps P. Cherepanov et al. Current opinion in structural Biology 2011
7 Hypothetical decay curve for plasma virus levels in a patient treated with HAART Blips
8 Barriers for Eradication
9 HIV-1 latent reservoirs are not eradicated by HAART HAART Host immune response Productively infected cells most commun - cell death (days) Uninfected CD4+ T lymphocytes Infected Latently infected cells rare event - long duration (months) HIV-1 RESERVOIRS POST-INTEGRATION or PROVIRAL LATENCY
10 The multifactorial nature of HIV post-integration latency 1. The site of integration into the host-cell genome, the cellular chromatin environment at this site and mechanisms of transcriptional interference 2. The absence of crucial inducible host transcription factors, such as NF- B, NFAT and STAT5, that are excluded from the nuclei of resting cells and transiently activated by various stimuli 3. The chromatin structure of the HIV-1 promoter and the presence of a repressive nucleosome (nuc-1) 4. The epigenetic control of the HIV-1 promoter (histone post-translational modifications [such acetylation and methylation] and DNA methylation) 5. The absence of the viral transactivator Tat, which promotes transcription by mediating the recruitment to the HIV-1 promoter of the kinase complex P-TEFb (CyclinT1/CDK9), of histone-modifying enzymes and of ATP-dependent chromatin-remodeling complexes required for nucleosomal disruption and transcriptional processivity 6. The sequestration of P-TEFb in a HEXIM/7SK snrna-bound inactive form
11 Eukaryotic DNA is packaged into chromatin nuc Heterochromatin : highly condensed chromatin structure (inactive genes) Euchromatin :a less compacted structure where genes are typically expressed
12 The HIV-1 integration sites and heterochromatic silencing Initial findings on the integration sites in a model cell line (J-Lat) indicated that latent provirus favoured heterochromatic regions, especially in or close to satellite repeat elements. However, an in vivo study of purified resting CD4+ T cells from HIV+ individuals on HAART revealed a strong preference for proviral integration in coding gene regions. This finding as been supported by several recent studies both in in vitro infected PBMCs and in several cell lines that confirmed preferential integration into transcriptional units.
13 Mechanisms of transcriptional interference Transcriptional interference due to integration into a higly transcribed gene can result in proviral latency. Transcriptional interference can occur through several different mechanisms including: - enhancer trapping - promoter occlusion - steric hindrance
14 Enhancer trapping: depending on the site of viral integration, the enhancer activity of the viral LTR can be hijacked by nearby host gene promoters Promoter 5 LTR Promoter occlusion: read-through from the cellular upstream promoter prevents assembly of the pre-initiation complex on the viral promoter Promoter 5 LTR Steric hindrance: RNA polymerases driven by opposing promoters collide, resulting in reduced transcription from the weaker promoter Promoter 3 LTR 5 LTR
15 The multifactorial nature of HIV post-integration latency 1. The site of integration into the host-cell genome, the cellular chromatin environment at this site and mechanisms of transcriptional interference 2. The absence of crucial inducible host transcription factors, such as NF- B, NFAT and STAT5, that are excluded from the nuclei of resting cells and transiently activated by various stimuli 3. The chromatin structure of the HIV-1 promoter and the presence of a repressive nucleosome (nuc-1) 4. The epigenetic control of the HIV-1 promoter (histone post-translational modifications [such acetylation and methylation] and DNA methylation) 5. The absence of the viral transactivator Tat, which promotes transcription by mediating the recruitment to the HIV-1 promoter of the kinase complex P-TEFb (CyclinT1/CDK9), of histone-modifying enzymes and of ATP-dependent chromatin-remodeling complexes required for nucleosomal disruption and transcriptional processivity 6. The sequestration of P-TEFb in a HEXIM/7SK snrna-bound inactive form
16 The multifactorial nature of HIV post-integration latency 1. The site of integration into the host-cell genome, the cellular chromatin environment at this site and mechanisms of transcriptional interference 2. The absence of crucial inducible host transcription factors, such as NF- B, NFAT and STAT5, that are excluded from the nuclei of resting cells and transiently activated by various stimuli 3. The chromatin structure of the HIV-1 promoter and the presence of a repressive nucleosome (nuc-1) 4. The epigenetic control of the HIV-1 promoter (histone post-translational modifications [such acetylation and methylation] and DNA methylation) 5. The absence of the viral transactivator Tat, which promotes transcription by mediating the recruitment to the HIV-1 promoter of the kinase complex P-TEFb (CyclinT1/CDK9), of histone-modifying enzymes and of ATP-dependent chromatin-remodeling complexes required for nucleosomal disruption and transcriptional processivity 6. The sequestration of P-TEFb in a HEXIM/7SK snrna-bound inactive form
17 Nucleosome disruption during transcriptional activation of the HIV-1 promoter nuc nuc-0 sites B nuc-1 nuc activation (TNF, PMA)
18 Nucleosomal structure
19 Covalent post-translational histone modifications p = phosphorylation, m = methylation, a = acetylation, Ub = ubiquitination, r = poly-adp-ribosylation epigenetic modifications: dynamic, rapidly changing depending on the signaling conditions within the cell, function sequentially or in combination to form the «histone code», which is read by effector proteins to produce distinct
20 The multifactorial nature of HIV post-integration latency 1. The site of integration into the host-cell genome, the cellular chromatin environment at this site and mechanisms of transcriptional interference 2. The absence of crucial inducible host transcription factors, such as NF- B, NFAT and STAT5, that are excluded from the nuclei of resting cells and transiently activated by various stimuli 3. The chromatin structure of the HIV-1 promoter and the presence of a repressive nucleosome (nuc-1) 4. The epigenetic control of the HIV-1 promoter (histone post-translational modifications [such acetylation and methylation] and DNA methylation) 5. The absence of the viral transactivator Tat, which promotes transcription by mediating the recruitment to the HIV-1 promoter of the kinase complex P-TEFb (CyclinT1/CDK9), of histone-modifying enzymes and of ATP-dependent chromatin-remodeling complexes required for nucleosomal disruption and transcriptional processivity 6. The sequestration of P-TEFb in a HEXIM/7SK snrna-bound inactive form
21 Agenda Mechanism Of HIV integration Of HIV latency Quantification of HIV Integration Quantification of HIV Reservoir The relation between residual viremia and integration events The relation between integration and latency Can we interfere with integration to diminish latency
22 Effect of Intensification on Persistent Viremia in all Patients Conclusion: No individual patient shows evidence of a decline in persistent viremia during intensification n
23 Quantification of HIV Integration: Alu-PCR to measure integrated HIV copies LTR LTR ALU ALU ALU PCR qpcr standardisation with cell culture NL4.3 on HeLaP4 cells: mix of different fragments to mimic in vivo situation
24 Drawbacks of Alu-HIV qpcr Variable sizes of Alu-HIV PCR amplicons in the first PCR the amount of Alu hybridization sites the nested PCR itself the background of unintegrated viral DNA the low amount of HIV DNA copies in HIV infected patients on HAART
25 Co-culture for quantification of latent reservoir 1. Isolation and purification of CD4+ CD25- HLA-DR- PBMC from HIV+ patients: latent memory CD4+ T lymfocytes 2. Uniform activation by addition of IL-2, PHA and irradiated PBMC in 10-fold from donors (macrophages, dendritic cells) 3. Amplify signal for p24 ELISA detection by addition d2/d7 of CD4+ CD8- lymfoblasts from donor
26 Co-culture for quantification of latent reservoir 1. Isolation and purification of CD4+ CD25- HLA-DR- PBMC from HIV+ patients: latent memory CD4+ T lymfocytes 2. Uniform activation by addition of IL-2, PHA and irradiated PBMC in 10-fold from donors (macrophages, dendritic cells) 3. Amplify signal for p24 ELISA detection by addition d2/d7 of CD4+ CD8- lymfoblasts from donor
27 Co-culture for quantification of latent reservoir 1. Isolation and purification of CD4+ CD25- HLA-DR- PBMC from HIV+ patients: latent memory CD4+ T lymfocytes 2. Uniform activation by addition of IL-2, PHA and irradiated PBMC in 10-fold from donors (macrophages, dendritic cells) 3. Amplify signal for p24 ELISA detection by addition d2/d7 of CD4+ CD8- lymfoblasts from donor
28 Co-culture for quantification of latent reservoir Patient: ml Hep blood to obtain 60mio memory CD4 lymfocytes PBMC from healthy donors: 2 buffy coats from blood bank per experiment Selection of CD4+ CD25- HLA-DR- T-lymfo s + Selection of CD8- PBMC (lymfoblast addition d2/d7/d15): MACS Separation columns with magnetic micro beads (Miltenyi Biotec) Lymphoprep (Ficoll gradient) 250ml per experiment Biochrome QG RPMI 1640 medium: 2L per experiment IL-2 (220 stock) + PHA Innogenetics Innotest HIV Ag mab (625 per 96well plate) Labor-intensive technique + costly!
29 The relation between number integration events and latency
30 Agenda Mechanism Of HIV integration Of HIV latency Quantification of HIV Integration Quantification of HIV Reservoir The relation between residual viremia and integration events The relation between integration and latency Can we interfere with integration to diminish latency and residual viremia?
31 MONOI ANRS patients A S48 A S96 HIV RNA < 50 cp ART duration 7.8 vs 8.7 CD4 Baseline : 582/ mm VL < 1 c/ml at BL VL > 50 c/ml at BL OR (IC 95 %) 0,24 (0,05-0,86) 7,84 (1,22-52,2) p OR (IC 95 %) 0,042-0,025 - p Nadir 220/mm 3 HIV RNA <1 cp (40%) HIV DNA 4 log 10 6 PBMC Poor Compliance (< 100 %) Prior duration ART (Increase by 5 years) HIV-1 DNA at D0 (log10 cells C/10 6) * ,84 (1,29-12,49) 2,93 (1,43-6,66) 2,66 (1,11-7,48) 0,02 0,00 6 0,04 HIV DNA is predictive of maintaining an HIV RNA <50 cp / ml on mono DRV at W96
32 HIV DNA Log copies/10 6 PBMC ANRS Cohorts : Cell-associated HIV-DNA Quantification inpbmc 6,00 Lewin and Rouzioux, Review, AIDS ,00 4,93 4,00 4,07 4,2 3,00 3,68 3,35 2,95 3,22 2,87 2,94 2,99 3,07 2,00 1,00 1,09 2,47 2,27 1,7 2,10 1,78 1,44 1,11 0,70 0,00 0,3 0,36 0,3 PRIMO inclusion SEROCO inclusion ALT HIC Visconti Primary infection Ghosn, JAC 2010 Seroco Rouzioux, JID 2005 ALT Martinez,JID 2008 Elite controllers Lambotte 2008 ART/PI Hocqueloux 2010
33 Visconti Patients 12 patients treated at Primary infection then stop ART Duration (med ): 35 months Duration Off ART : 5 years CD4 -pre ART 489 ( ) -at ART stop: 931 ( last value : 837( HIV RNA - preart : 5.0 log ( 3-7.3) - last value : 1.7 log ( ) A. Saez-Cirion et al., # F-126 CROI 2011 (Boston)
34 127 ART treated patients Med Duration : 6.5 y CD4 med : 580 /mm3 HIV RNA ( taqman)< 50 cp : 100% CD4/CD8 : 0.8 HIV RNA us < 1 cp/ml: 37% CV median: 2.6 cp/ml Correlation between residual HIV RNA and CD4/CD8 and DNA No association between residual HIV RNA and activation markers (CRP, IL6, stnf, CD38) J Infect Dis Jul;204(1):
35 Agenda Mechanism Of HIV integration Of HIV latency Quantification of HIV Integration Quantification of HIV Reservoir The relation between residual viremia and integration events The relation between integration and latency Can we interfere with integration to diminish latency and residual viremia?
36 The relation between integration and latency
37 The relation between integration and latency
38 The relation between site of integration and latency
39 The relation between site of integration and latency Integration sites were enriched within active transcription units in both cell types
40 Agenda Mechanism Of HIV integration Of HIV latency Quantification of HIV Integration Quantification of HIV Reservoir The relation between residual viremia and integration events The relation between integration and latency Can we interfere with integration to diminish latency and residual viremia?
41 Can we interfere with integration to diminish latency (and residual viremia)? R.T Gandghi, Plos Med 2010
42 Can we interfere with integration to diminish latency and residual viremia?
43 Shortcommings of intensification studies
44 Can we interfere with the integration site selection
45 Different patients respond different to antilatency cocktail S.Reuze, Plos One 2009
46 Can we interfere with the integration site selection
47 Can we interfere with the integration site selection H.M. Marshall, Plos One 2007
48 Can we interfere with the integration site selection H.M. Marshall, Plos One 2007
49 Agenda Mechanism Of HIV integration Of HIV latency Quantification of HIV Integration Quantification of HIV Reservoir The relation between integration and latency The relation between residual viremia and integration events Can we interfere with integration to diminish latency and residual viremia?
50 Take home message The relation between integration and latency Latency can be established by several molecular mechanisms of which some of them are influenced by the site of integration The relation between residual viremia and integration events The number of integration events seems to be related to a phenotype of disease progression and therefore this could serve as an important tool in a diagnostic setting
51 Take home message Can we interfere with integration to diminish latency and residual viremia? ART compounds that interfere with integration/integration site selection are the preferred compounds that might directly influence latency, however integration events might also be diminsdhed by antilatency compounds that affect eg epigenetic regulation, NF- B, NFAT and STAT... A combination of new diagnostic tools to assess the extend of the reservoir will help evaluating this new drugs
Human Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationHIV INFECTION: An Overview
HIV INFECTION: An Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL MBBS II SEMINAR VJ
More informationHIV & AIDS: Overview
HIV & AIDS: Overview UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR VJ TEMPLE 1 What
More informationTowards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir.
Abstract no. MOLBPEA13 Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir. G. Vansant,,A. Bruggemans, L. Vranckx, S. Saleh, I. Zurnic, F. Christ,
More informationHIV-DNA: nuovo marcatore virologico. Metodiche a confronto per la quantificazione di HIV-DNA
HIV-DNA: nuovo marcatore virologico Metodiche a confronto per la quantificazione di HIV-DNA Maria Carla Re Laboratorio Retrovirus e Agenti infettivi HIV correlati UO di Microbiologia, Università di Bologna
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationFig. 1: Schematic diagram of basic structure of HIV
UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR HIV & AIDS: An Overview What is HIV?
More informationL I F E S C I E N C E S
1a L I F E S C I E N C E S 5 -UUA AUA UUC GAA AGC UGC AUC GAA AAC UGU GAA UCA-3 5 -TTA ATA TTC GAA AGC TGC ATC GAA AAC TGT GAA TCA-3 3 -AAT TAT AAG CTT TCG ACG TAG CTT TTG ACA CTT AGT-5 OCTOBER 31, 2006
More informationHIV Immunopathogenesis. Modeling the Immune System May 2, 2007
HIV Immunopathogenesis Modeling the Immune System May 2, 2007 Question 1 : Explain how HIV infects the host Zafer Iscan Yuanjian Wang Zufferey Abhishek Garg How does HIV infect the host? HIV infection
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationTranscriptional control in Eukaryotes: (chapter 13 pp276) Chromatin structure affects gene expression. Chromatin Array of nuc
Transcriptional control in Eukaryotes: (chapter 13 pp276) Chromatin structure affects gene expression Chromatin Array of nuc 1 Transcriptional control in Eukaryotes: Chromatin undergoes structural changes
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationlevels of genes were separated by their expression levels; 2,000 high, medium, and low
Figure S1. Histone modification profiles near transcription start sites. The overall histone modification around transcription start sites (TSSs) was calculated. Histone modification levels of genes were
More informationSection 6. Junaid Malek, M.D.
Section 6 Junaid Malek, M.D. The Golgi and gp160 gp160 transported from ER to the Golgi in coated vesicles These coated vesicles fuse to the cis portion of the Golgi and deposit their cargo in the cisternae
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationHIV/AIDS. Biology of HIV. Research Feature. Related Links. See Also
6/1/2011 Biology of HIV Biology of HIV HIV belongs to a class of viruses known as retroviruses. Retroviruses are viruses that contain RNA (ribonucleic acid) as their genetic material. After infecting a
More informationUnder the Radar Screen: How Bugs Trick Our Immune Defenses
Under the Radar Screen: How Bugs Trick Our Immune Defenses Session 7: Cytokines Marie-Eve Paquet and Gijsbert Grotenbreg Whitehead Institute for Biomedical Research HHV-8 Discovered in the 1980 s at the
More informationCan we eradicate HIV?
Can we eradicate HIV? New therapeutic strategies towards a cure Laurence COLIN Laboratory of Molecular Virology University of Brussels Belgium The success story of HAART encountered solid barriers to virus
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationHIV transcription, Tat transactivation mrna processing and latency
HIV transcription, Tat transactivation mrna processing and latency Tat transactivation Roles of CTD kinases in HIV replication Latency and reservoir Strategies to eliminate the reservoir of HIV in the
More informationThe HIV life cycle. integration. virus production. entry. transcription. reverse transcription. nuclear import
The HIV life cycle entry reverse transcription transcription integration virus production nuclear import Hazuda 2012 Integration Insertion of the viral DNA into host chromosomal DNA, essential step in
More informationTargeting latent HIV infection: on the road towards an HIV Cure
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Targeting latent HIV infection: on the road towards an HIV Cure David M. Margolis, MD Professor of Medicine Treatment Cure Prevention Prevention
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationThe molecular mechanisms of latency and reactivation in CD4 + T cells during HIV infection Suzanna Huppelschoten
The molecular mechanisms of latency and reactivation in CD4 + T cells during HIV infection Suzanna Huppelschoten March, 2011 Masterthesis Infection and Immunity Written under supervision of L.M van den
More informationBiol115 The Thread of Life"
Biol115 The Thread of Life" Lecture 9" Gene expression and the Central Dogma"... once (sequential) information has passed into protein it cannot get out again. " ~Francis Crick, 1958! Principles of Biology
More informationRetroviruses. ---The name retrovirus comes from the enzyme, reverse transcriptase.
Retroviruses ---The name retrovirus comes from the enzyme, reverse transcriptase. ---Reverse transcriptase (RT) converts the RNA genome present in the virus particle into DNA. ---RT discovered in 1970.
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More informationCDC site UNAIDS Aids Knowledge Base http://www.cdc.gov/hiv/dhap.htm http://hivinsite.ucsf.edu/insite.jsp?page=kb National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/default.htm
More informationPathogenesis Update Robert F. Siliciano, MD, PhD
Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationDevelopment of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
Trejbalová et al. Clinical Epigenetics (2016) 8:19 DOI 10.1186/s13148-016-0185-6 RESEARCH Development of 5 LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals
More informationEukaryotic Gene Regulation
Eukaryotic Gene Regulation Chapter 19: Control of Eukaryotic Genome The BIG Questions How are genes turned on & off in eukaryotes? How do cells with the same genes differentiate to perform completely different,
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More information, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic
1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in
More informationAcquired immune deficiency syndrome.
Acquired immune deficiency syndrome 491 Acquired immune deficiency syndrome. The first cases of acquired immune deficiency syndrome (AIDS) were reported in 1981 but it is now clear that cases of the disease
More informationDUAL CONTROL OF HIV TRANSCRIPTION ELONGATION: VIRUS- SPECIFIC NEGATIVE CONTROL BY NELF-E IS COUNTERBALANCED BY POSITIVE TRANSCRIPTION FACTOR P-TEFb
DUAL CONTROL OF HIV TRANSCRIPTION ELONGATION: VIRUS- SPECIFIC NEGATIVE CONTROL BY NELF-E IS COUNTERBALANCED BY POSITIVE TRANSCRIPTION FACTOR P-TEFb By JULIE K. JADLOWSKY Submitted in partial fulfillment
More informationEukaryotic transcription (III)
Eukaryotic transcription (III) 1. Chromosome and chromatin structure Chromatin, chromatid, and chromosome chromatin Genomes exist as chromatins before or after cell division (interphase) but as chromatids
More informationEradicating HIV-1 infection: seeking to clear a persistent pathogen
Eradicating HIV-1 infection: seeking to clear a persistent pathogen Nancie M. Archin 1, Julia Marsh Sung 1, Carolina Garrido 1, Natalia Soriano-Sarabia 1 and David M. Margolis 1 3 Abstract Effective antiretroviral
More informationRecombinant Protein Expression Retroviral system
Recombinant Protein Expression Retroviral system Viruses Contains genome DNA or RNA Genome encased in a protein coat or capsid. Some viruses have membrane covering protein coat enveloped virus Ø Essential
More informationLentiviruses: HIV-1 Pathogenesis
Lentiviruses: HIV-1 Pathogenesis Human Immunodeficiency Virus, HIV, computer graphic by Russell Kightley Tsafi Pe ery, Ph.D. Departments of Medicine and Biochemistry & Molecular Biology NJMS, UMDNJ. e-mail:
More informationCh. 18 Regulation of Gene Expression
Ch. 18 Regulation of Gene Expression 1 Human genome has around 23,688 genes (Scientific American 2/2006) Essential Questions: How is transcription regulated? How are genes expressed? 2 Bacteria regulate
More informationHIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
More informationHIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
More informationOctober 26, Lecture Readings. Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell
October 26, 2006 Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell 1. Secretory pathway a. Formation of coated vesicles b. SNAREs and vesicle targeting 2. Membrane fusion a. SNAREs
More information5/6/17. Diseases. Disease. Pathogens. Domain Bacteria Characteristics. Bacteria Viruses (including HIV) Pathogens are disease-causing organisms
5/6/17 Disease Diseases I. II. Bacteria Viruses (including HIV) Biol 105 Chapter 13a Pathogens Pathogens are disease-causing organisms Domain Bacteria Characteristics 1. Domain Bacteria are prokaryotic.
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Cryopreservation alters CD62L expression by CD4 T cells. Freshly isolated (left) or cryopreserved PBMCs (right) were stained with the mix of antibodies described
More informationSupplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR
Supplemental Materials and Methods Plasmids and viruses To generate pseudotyped viruses, the previously described recombinant plasmids pnl4-3-δnef-gfp or pnl4-3-δ6-drgfp and a vector expressing HIV-1 X4
More informationThe HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
More informationEXOSOMES FROM UNINFECTED CELLS ACTIVATE TRANSCRIPTION OF LATENT HIV-1
JBC Papers in Press. Published on May 23, 2017 as Manuscript M117.793521 The latest version is at http://www.jbc.org/cgi/doi/10.1074/jbc.m117.793521 EXOSOMES FROM UNINFECTED CELLS ACTIVATE TRANSCRIPTION
More informationProkaryotic Biology. VIRAL STDs, HIV-1 AND AIDS
Prokaryotic Biology VIRAL STDs, HIV-1 AND AIDS Prokaryotic Biology FROM THE CDC VIRAL STDs, HIV-1 AND AIDS VIRAL STDs & CONTACT VIRAL DISEASES A. GENITAL HERPES & COLD SORES 1. HERPES SIMPLEX VIRUS-2 (HHV-2)
More informationLecture Readings. Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell
October 26, 2006 1 Vesicular Trafficking, Secretory Pathway, HIV Assembly and Exit from Cell 1. Secretory pathway a. Formation of coated vesicles b. SNAREs and vesicle targeting 2. Membrane fusion a. SNAREs
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationCombining Pharmacology and Mutational Dynamics to Understand and Combat Drug Resistance in HIV
Combining Pharmacology and Mutational Dynamics to Understand and Combat Drug Resistance in HIV A dissertation submitted for the degree of Doctor of Philosophy by Max von Kleist, B.Sc., M.Sc. Supervisor:
More informationHIV-1 regulation of latency in the monocytemacrophage. lymphocytes
Review HIV-1 regulation of latency in the monocytemacrophage lineage and in CD4 T lymphocytes Laetitia Redel,* Valentin Le Douce,* Thomas Cherrier,* Céline Marban,* Andrea Janossy,* Dominique Aunis,* Carine
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationDeterminants of the Establishment of Human Immunodeficiency Virus Type 1 Latency
JOURNAL OF VIROLOGY, Apr. 2009, p. 3078 3093 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02058-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Determinants of the Establishment
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationCenters for Disease Control August 9, 2004
HIV CDC site UNAIDS Aids Knowledge Base http://www.cdc.gov/hiv/dhap.htm http://hivinsite.ucsf.edu/insite.jsp?page=kb National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/default.htm
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationMechanisms of alternative splicing regulation
Mechanisms of alternative splicing regulation The number of mechanisms that are known to be involved in splicing regulation approximates the number of splicing decisions that have been analyzed in detail.
More informationIdentification and Characterization of CD4 T cells actively transcribing HIV RNA in Peripheral Blood
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Identification and Characterization of CD4 T cells actively transcribing
More informationStructure of HIV. Virion contains a membrane envelope with a single viral protein= Env protein. Capsid made up of Gag protein
Structure of HIV Virion contains a membrane envelope with a single viral protein= Env protein Important in receptor recognition Capsid made up of Gag protein (group-specific antigen) Icosahedral Interior
More informationLTR R U5 PBS. 5' LTR : weak promoter [Inr, TATA-box, and three Sp1 sites] + enhancer elements.
Foreword HIV has a very complex system of transcription regulation and mrna splicing. This produces something that approximates "life-cycle" stages. Expression from the promoter always occurs but at first
More informationCDC site UNAIDS Aids Knowledge Base http://www.cdc.gov/hiv/dhap.htm http://hivinsite.ucsf.edu/insite.jsp?page=kb National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/default.htm
More informationNature Medicine: doi: /nm.2109
HIV 1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs Christoph C. Carter, Adewunmi Onafuwa Nuga, Lucy A. M c Namara, James Riddell IV, Dale Bixby, Michael
More informationRunning Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS. An Understanding of HIV- 1, Symptoms, and Treatments.
Running Head: AN UNDERSTANDING OF HIV- 1, SYMPTOMS, AND TREATMENTS An Understanding of HIV- 1, Symptoms, and Treatments Benjamin Mills Abstract HIV- 1 is a virus that has had major impacts worldwide. Numerous
More informationCitation for published version (APA): Von Eije, K. J. (2009). RNAi based gene therapy for HIV-1, from bench to bedside
UvA-DARE (Digital Academic Repository) RNAi based gene therapy for HIV-1, from bench to bedside Von Eije, K.J. Link to publication Citation for published version (APA): Von Eije, K. J. (2009). RNAi based
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. 1 Virion Entry Life Cycle of Entry 1 virion 1 Virus virion envelope Cell CD4membrane receptor RELEASE OF PROGENY VIRUS REVERSE Coreceptor TRANSCRIPTION
More informationTranscriptional Interference Antagonizes Proviral Gene Expression to Promote HIV Latency
Article Transcriptional Interference Antagonizes Proviral Gene Expression to Promote HIV Latency Tina Lenasi, 1, * Xavier Contreras, 1 and B. Matija Peterlin 1, * 1 Departments of Medicine, Microbiology,
More informationHIV Diagnosis and Pathogenesis. HIV-1 Virion
HIV Diagnosis and Pathogenesis Scott M. Hammer, M.D. HIV1 Virion Life Cycle of HIV HIV1 virion HIV1 Virus virion envelope Cell CD4membrane receptor VIRUS BINDING AND ENTRY RELEASE OF PROGENY VIRUS REVERSE
More informationLaboratory diagnostics CH/HIV/0052/17/10/2017
Laboratory diagnostics CH/HIV/0052/17/10/2017 This slide set was created by ViiV Healthcare GmbH with great care in order to provide balanced information about ViiV products and / or application areas.
More informationRegulation of Gene Expression in Eukaryotes
Ch. 19 Regulation of Gene Expression in Eukaryotes BIOL 222 Differential Gene Expression in Eukaryotes Signal Cells in a multicellular eukaryotic organism genetically identical differential gene expression
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationGene Expression DNA RNA. Protein. Metabolites, stress, environment
Gene Expression DNA RNA Protein Metabolites, stress, environment 1 EPIGENETICS The study of alterations in gene function that cannot be explained by changes in DNA sequence. Epigenetic gene regulatory
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More information19 Viruses BIOLOGY. Outline. Structural Features and Characteristics. The Good the Bad and the Ugly. Structural Features and Characteristics
9 Viruses CAMPBELL BIOLOGY TENTH EDITION Reece Urry Cain Wasserman Minorsky Jackson Outline I. Viruses A. Structure of viruses B. Common Characteristics of Viruses C. Viral replication D. HIV Lecture Presentation
More informationTranscription and RNA processing
Transcription and RNA processing Lecture 7 Biology 3310/4310 Virology Spring 2018 It is possible that Nature invented DNA for the purpose of achieving regulation at the transcriptional rather than at the
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationTat inhibition by didehydro Cortistatin A promotes heterochromatin formation at the HIV 1 long terminal repeat
https://doi.org/10.1186/s13072-019-0267-8 Epigenetics & Chromatin RESEARCH Open Access Tat inhibition by didehydro Cortistatin A promotes heterochromatin formation at the HIV 1 long terminal repeat Chuan
More informationCURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES
[Frontiers in Bioscience 5, d527-555, May 1, 2000] CURRENT DEVELOMENTS AND FUTURE PROSPECTS FOR HIV GENE THERAPY USING INTERFERING RNA-BASED STRATEGIES Betty Lamothe, Sadhna Joshi Department of Medical
More informationInhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers
JOURNAL OF VIROLOGY, Sept. 2011, p. 9646 9650 Vol. 85, No. 18 0022-538X/11/$12.00 doi:10.1128/jvi.05327-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Inhibition of HIV-1 Integration
More informationAsier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France
Infection à VIH : une rémission possible Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Viral reservoirs persist in HIV-infected individuals receiving
More informationHIV and drug resistance Simon Collins UK-CAB 1 May 2009
HIV and drug resistance Simon Collins UK-CAB 1 May 2009 slides: thanks to Prof Clive Loveday, Intl. Clinical Virology Centre www.icvc.org.uk Tip of the iceberg = HIV result, CD4, VL Introduction: resistance
More informationViral Genetics. BIT 220 Chapter 16
Viral Genetics BIT 220 Chapter 16 Details of the Virus Classified According to a. DNA or RNA b. Enveloped or Non-Enveloped c. Single-stranded or double-stranded Viruses contain only a few genes Reverse
More informationHerpesviruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Herpesviruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped icosahedral capsid (T=16), diameter 125 nm Diameter of enveloped virion 200 nm Capsid
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 RETROVIRUSES. 2. HTLV-II causes hairy T-cell leukemia
1 of 7 I. Diseases Caused by Retroviruses RETROVIRUSES A. Human retroviruses that cause cancers 1. HTLV-I causes adult T-cell leukemia and tropical spastic paraparesis 2. HTLV-II causes hairy T-cell leukemia
More informationDIFFERENTIAL IMPACT OF HIV-1 PROTEASE INHIBITORS ON SUBSETS OF CD4+ T-LYMPHOCYTES
DIFFERENTIAL IMPACT OF HIV-1 PROTEASE INHIBITORS ON SUBSETS OF CD4+ T-LYMPHOCYTES By CHRISTINA GAVEGNANO A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF
More informationEpigenetics. Lyle Armstrong. UJ Taylor & Francis Group. f'ci Garland Science NEW YORK AND LONDON
... Epigenetics Lyle Armstrong f'ci Garland Science UJ Taylor & Francis Group NEW YORK AND LONDON Contents CHAPTER 1 INTRODUCTION TO 3.2 CHROMATIN ARCHITECTURE 21 THE STUDY OF EPIGENETICS 1.1 THE CORE
More informationOncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir
Oncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir Costiniuk CT, Côté SC, Al-Ghazawi FM, Carrasco-Medina L,Young CD, & Angel JB University of Ottawa, November 12 th, 2012 HIV Reservoirs
More informationFor all of the following, you will have to use this website to determine the answers:
For all of the following, you will have to use this website to determine the answers: http://blast.ncbi.nlm.nih.gov/blast.cgi We are going to be using the programs under this heading: Answer the following
More informationDecay characteristics of HIV-1- infected compartments during combination therapy
Decay characteristics of HIV-1- infected compartments during combination therapy Perelson et al. 1997 Kelsey Collins BIOL0380 September 28, 2009 SUMMARY Analyzed decay patterns of viral load of HIV- 1-infected
More informationHIV-1 Tat complexes reveal subunit composition of active P-TEFb and stable association with 7SKsnRNP
HIV-1 Tat complexes reveal subunit composition of active P-TEFb and stable association with 7SKsnRNP Bijan Sobhian and Monsef Benkirane (Institute of human genetics, Montpellier, France) Many ways to activate
More informationBeyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013
8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of
More informationEpigenetics: The Future of Psychology & Neuroscience. Richard E. Brown Psychology Department Dalhousie University Halifax, NS, B3H 4J1
Epigenetics: The Future of Psychology & Neuroscience Richard E. Brown Psychology Department Dalhousie University Halifax, NS, B3H 4J1 Nature versus Nurture Despite the belief that the Nature vs. Nurture
More informationI. Bacteria II. Viruses including HIV. Domain Bacteria Characteristics. 5. Cell wall present in many species. 6. Reproduction by binary fission
Disease Diseases I. Bacteria II. Viruses including are disease-causing organisms Biol 105 Lecture 17 Chapter 13a Domain Bacteria Characteristics 1. Domain Bacteria are prokaryotic 2. Lack a membrane-bound
More information